Anavex Life Sciences Corp. (AVXL)
| Previous close | 8.90 |
| Open | 9.06 |
| Bid | 9.05 x 900 |
| Ask | 9.07 x 900 |
| Day's range | 9.03 - 9.36 |
| 52-week range | 7.13 - 23.73 |
| Volume | |
| Avg. volume | 783,747 |
| Market cap | 713.177M |
| Beta (5Y monthly) | 0.82 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.58 |
| Earnings date | 22 Nov 2022 - 28 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 35.33 |
- GlobeNewswire
Anavex Life Sciences Announces Issuance of U.S. Patent Covering ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders Therapy
Issuance of Anavex’s Newest U.S. Patent Will Expand Anavex’s Intellectual Property Portfolio Surrounding ANAVEX®2-73NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders
- GlobeNewswire
Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation to Compensate for Early Alzheimer's Disease
Mechanism of Action of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) is the activation of SIGMAR1 Endogenous increase in SIGMAR1 activation as a compensatory mechanism against early Alzheimer's disease Top line results of randomized, placebo-controlled Phase 2b/3 study ANAVEX®2-73-AD-004 for the treatment of early Alzheimer's disease are expected in the fall of 2022 NEW YORK, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical
- Simply Wall St.
Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
